EssilorLuxottica Showcases Integrated Vision Care

EssilorLuxottica said this was the first time that a coordinated scientific program had spanned the entire eye care continuum. 

Vision Care and Med Tech 

Combining capabilities in vision care and medical technologies – including Heidelberg Engineering, RetinAI, and Espansione – the group demonstrated how it integrates technologies, data, and clinical expertise within a unified, science-led ecosystem. 

EssilorLuxottica said the “integrated model brings together myopia management and vision science, advanced diagnostics, AI-driven analytics, and technology-enabled therapeutic solutions to support more holistic, data-driven patient care”. 

At ARVO, EssilorLuxottica presented more than 20 peer-reviewed scientific abstracts, which it said underscored the depth of its research. 

“The integration of advanced imaging, AI-driven analytics, and therapeutic technologies is transforming how we understand and manage eye diseases,” said Norbert Gorny, Chief Scientific Officer at EssilorLuxottica. 

“At ARVO 2026, we demonstrated how these capabilities enable a more connected, data-driven approach to eye care, from earlier detection to more informed patient management.” 

Med-Tech Advances 

EssilorLuxottica also showcased innovations in medical technologies, highlighting its role in enabling earlier insights, improving clinical decision making, and advancing more personalised care. 

“Heidelberg Engineering’s pioneering work in multimodal imaging with ultra-high-resolution OCT and fully digital surgical microscopy is opening a new era in imaging and surgery. Together with RetinAI’s AI-powered insights and Espansione’s treatment options, we are transforming science into meaningful impact for patients, clinicians, researchers, and the future of eye care”, said Ettore Mosca, Head of Medical Technologies at EssilorLuxottica. 

Myopia Management 

Among the studies presented on myopia management were the long-term results from a seven-year follow-up study of Essilor Stellest highly aspherical lenslets (HAL) spectacle lenses in China. The study demonstrated sustained efficacy in children and adolescents. The lenses slowed myopia progression by 2.30 D and axial elongation by 0.92 mm, on average, for all subjects over seven years.¹  

The outcomes observed in adolescents up to 19 years of age also showed a reduced risk of developing high myopia with Essilor Stellest lens wear over seven years compared with single vision lenses.  

Results from a prospective, randomised, multicentre clinical trial conducted in the United States among children aged six to twelve demonstrated that Essilor Stellest lenses slowed myopia progression by 71% on average and axial elongation by 53% over two years, compared with single vision lenses.² 

Efficacy was observed across all age groups and baseline myopia levels, with stronger effects seen in younger children.³ 

The study also demonstrated a favourable safety profile, with stable visual acuity and high compliance and retention over two years.⁴ Additional analyses indicated no impact on the rate of astigmatism change over two years,⁵ confirming previously reported results in Chinese paediatric populations.^6,7  

Evidence Across Clinical Settings and Patient Populations 

EssilorLuxottica said findings presented at ARVO further reinforced the integrated evidence base supporting HAL spectacle lenses across clinical trials, real-world clinical practice, and diverse patient populations. 

A review of published evidence across 26 studies conducted in multiple patient populations, including 17 in China, showed consistent findings for Essilor Stellest lenses, Essilor Luxottica said.  

Among the 10 studies that included a single vision lens control group, axial elongation in children wearing HAL spectacle lenses was consistently lower than in those wearing single vision lenses, regardless of study design or geographic location.⁹  

EssilorLuxottica said real-world evidence presented at ARVO 2026 and later published in Ophthalmology Science¹⁰ showed that different spectacle lens designs slowed myopia progression in clinical practice compared with single vision lenses. 

HAL spectacle lenses were associated with the largest reduction in axial length in this retrospective cohort study. Additional real-world evidence in children with low myopia further supported HAL lenses as showing the most robust myopia progression control effect across spectacle lens designs.¹¹ 

Research presented at ARVO 2026 also highlighted the potential benefit of combination approaches to myopia management. An independent study showed that combining HAL spectacle lenses with low-dose atropine maintained strong myopia progression control over 24 months, compared with atropine alone.¹² 

Another large school-based study in Shanghai demonstrated that integrated interventions, including HAL lens wear and increased outdoor time, may help reduce incident myopia and slow axial elongation in myopic and pre-myopic children.¹³ 

References 

1. Li X, Huang Y, Bao J, et al. Myopia control efficacy of spectacle lenses with highly asphericallenslets: Results of a 7-year follow-up study. ARVO 2026 Annual Meeting; 2026 May 3–7; Denver, CO. Poster 0968. 
2. Shen J, et al.Two yearsafety and effectiveness of Stellest lenses for slowing myopia progression in a US pediatric population. ARVO 2026 Annual Meeting; 2026 May 3–7; Denver, CO. Poster 1229-0999. 
3. Lim EW, Shen J,DrobeB, et al. Impact of age and baseline myopia on the effectiveness of Stellest lenses in a US paediatric population. ARVO 2026 Annual Meeting; 2026 May 3–7; Denver, CO. Poster 1196-09664.  
4. Gelb C, et al. Safety and visual acuity outcomes ofStellestlenses: 2-year results from a US pivotal trial. ARVO 2026 Annual Meeting; 2026 May 3–7; Denver, CO. Poster 1201-0971. 
5. Wong YL, et al. Comparison of 24-month astigmatism changes betweenStellestand single vision lenses in US children. ARVO 2026 Annual Meeting; 2026 May 3–7; Denver, CO. Poster 1229-0967 
6. Bao J,Huang Y, Chen H,et al. Two-year changes in cylinder power in myopic children wearing spectacle lenses with highly aspherical lenslets and single vision spectacle lenses. Invest. Ophthalmol. Vis. Sci. 2024 Jun 17;65(7):160-.9. 
7. Wen K,Yang B, Liu L, Cho P. Effect ofthree types of specially-designed myopia control spectacle lenses on astigmatism: A two-year result. Ophthalmic Physiol Opt. 2026 Apr 8. doi: 10.1007/s44402-026-00077-5. Epub ahead of print. 
8. U.S. FDA. FDA authorizes marketing of first eyeglass lenses to slow progression ofpediatricmyopia. Sep 2025. Available at: fda.gov/news-events/press-announcements/fda-authorizes-marketing-first-eyeglass-lenses-slow-progression-pediatric-myopia [accessed May 2026]. 
9. BullimoreM, Prenat O. Myopia control with spectacle lenses with highly aspherical lenslets (HAL). ARVO 2026 Annual Meeting; 2026 May 3–7; Denver, CO. Poster 0978 8. 
10. Ganesh SC, Armentano M, Narendran K, et al. Comparative effectiveness of myopia-control spectacle lenses:Clincial setting performance from a retrospective cohort study. Ophthalmol Sci. 2026 Feb 2;6(4):101103. doi: 10.1016/j.xops.2026.101103. 
11. Liu C, et al. Real-world effectiveness of three myopia-control spectacle lens designs in children with low myopia. ARVO 2026 Annual Meeting; 2026 May 3-7; Denver, CO. Poster 1223-0993.
12. Sim B, et al. Efficacyof combined highly asphericallenslet target (HALT) spectacles and low-dose atropine in children with poor response to atropine monotherapy over 24 months. ARVO 2026 Annual Meeting; 2026 May 3‑7; Denver, CO. Poster 1002; 
13. He J, et al. Theschool-based myopia prevention and control integrated studyin Shanghai：6-month results. ARVO 2026 Annual Meeting; 2026 May 3‑7; Denver, CO. Presentation 1879.